Table 5. Relationship between the detection of Staphylococcus haemolyticus and/or Ralstonia pickettii and the baseline characteristics of the recipients.
| Either/both of the two taxa | |||
|---|---|---|---|
| Detected | Not detected | ||
| (n = 17) | (n = 28) | P-valuea | |
| Age (Mean ±SD) | 54±10 | 51±10 | 0.46a |
| No. (%) of female | 9 (52.9) | 10 (35.7) | 0.35b |
| Underlying disease | 0.73b | ||
| Acute myelogenous leukemia | 8 (47.0) | 15 (53.5) | |
| Malignant lymphoma | 5 (29.4) | 5 (17.8) | |
| Acute lymphoblastic leukemia | 1 (5.8) | 4 (14.2) | |
| Myelodysplastic syndrome | 2 (11.7) | 3 (10.7) | |
| Primary myelofibrosis | 0 (0) | 1 (3.5) | |
| Aplastic anemia | 1 (5.8) | 0 (0) | |
| Prior transplantation | 2 (11.7) | 4 (14.2) | 1.00b |
| Risk status at transplantation | 0.06b | ||
| Standard | 5 (29.4) | 17 (60.7) | |
| High | 12 (70.5) | 11 (39.2) | |
| Conditioning regimens | 0.37b | ||
| Myeloablative | 6 (35.2) | 14 (50.0) | |
| Reduced intensity | 11 (64.7) | 14 (50.0) | |
| Antibiotic use during conditioning | 0.001b | ||
| Prophylactic use | 2 (11.7) | 17 (60.7) | |
| Additional use for treatment | 15 (88.2) | 11 (39.2) | |
| Total body irradiation | 0.72b | ||
| None | 4 (23.5) | 6 (21.4) | |
| Low dose | 9 (52.9) | 12 (42.8) | |
| High dose | 4 (23.5) | 10 (35.7) | |
| Graft source | 0.07b | ||
| Peripheral blood | 11 (64.7) | 10 (35.7) | |
| Bone marrow | 4 (23.5) | 16 (57.1) | |
| Cord blood | 2 (11.7) | 2 (7.1) | |
| HLA parity | 0.23b | ||
| Matched | 7 (41.1) | 17 (60.7) | |
| Mismatched | 10 (58.8) | 11 (39.2) | |
| GvHD prophylaxis | 0.41b | ||
| CIs+sMTX | 10 (58.8) | 22 (78.5) | |
| CIs+MMF±PTCy | 5 (29.4) | 4 (14.2) | |
| Others | 2 (11.7) | 2 (7.1) | |
aStudent’s t-test.
bFisher’s exact test.
Abbreviation: GvHD, graft-versus host disease; CIs, calcineurin inhibitors; MTX, methotrexate; MMF, mycophenolate mofetil; PTCy, post-transplant cyclophosphamide.